Refametinib
Refametinib Uses, Dosage, Side Effects, Food Interaction and all others data.
Trade Name | Refametinib |
Generic | Refametinib |
Refametinib Other Names | Refametinib |
Type | |
Formula | C19H20F3IN2O5S |
Weight | Average: 572.337 Monoisotopic: 572.008970485 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in cancer/tumors (unspecified).
How Refametinib works
RDEA119 is a potent, non-ATP competitive, highly selective inhibitor of MEK. RDEA119 is a highly potent and selective inhibitor of mitogen-activated ERK kinase (MEK), a key component of the RAS/RAF/MEK/ERK pathway that is commonly defective in human tumors. The MEK1/2 pathway is important in cell cycle regulation in inflammatory bowel disease, including ulcerative colitis and Crohn's disease. RDEA119 was shown to reduce damage to colonic tissue in two different mouse models of colitis, murine trinitrobenzene sulfonic acid (TNBS) colitis model and murine dextran sulfate sodium (DSS) colitis model. [Ardea Biosciences Inc. Press release]
Innovators Monograph
You find simplified version here Refametinib